Rutgers New Jersey Medical School

Summary

Rutgers New Jersey Medical School is a medical facility located in Newark, New Jersey. This center is recognized for care of HIV Infection, Human Immunodeficiency Virus Infection, Breast Cancer, Breast cancer, Tuberculosis and other specialties. Rutgers New Jersey Medical School is involved with conducting 194 clinical trials across 343 conditions. There are 22 research doctors associated with this hospital, such as Howard S. Hochster, Eugenia Girda, MD, Missak Haigentz, MD, and Mridula George, MD.

Top PIs

Clinical Trials running at Rutgers New Jersey Medical School

Oropharyngeal Carcinoma

Prostate Cancer

Laryngeal Cancer

Kidney Cancer

Pulmonary Embolism

Uterine Cancer

Lip and Oral Cavity Cancer

Throat Cancer

Lung Cancer

Oral Squamous Cell Carcinoma

Ipatasertib + Chemoradiation

for Head and Neck Cancer

This trial tests the safety and best dose of ipatasertib combined with chemo-radiation in patients with advanced head and neck cancer. Ipatasertib may help stop or kill cancer cells by blocking a protein they need to grow. The goal is to see if this combination works better than chemo-radiation alone.

Recruiting

1 award

Phase 1

19 criteria

Radiation Therapy + Cisplatin

for Head and Neck Cancer

This trial is studying if using a specific type of energy treatment alone or with a drug is better for treating patients with advanced head and neck cancer after surgery. The energy treatment kills cancer cells, and the drug helps by stopping their growth or killing them. The drug has been used for many years in the treatment of advanced cancers, including head and neck cancers, and is known for its ability to enhance the effects of the energy treatment.

Recruiting

1 award

Phase 2

19 criteria

Chemotherapy + Radiation Therapy

for Head and Neck Cancer

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab.

Recruiting

1 award

Phase 2 & 3

21 criteria